Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Boan Biotechnology CoFRA:UJ9 39 Days Inventory is 222.57 as of Dec. 2025, which is 22% below its 10-year median of 284.24. GuruFocus rates FRA:UJ9 with a GF Score™ of 39/100 and a GF Value™ of €1.72. The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, Shandong Boan Biotechnology Co ranks worse than 60.19% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shandong Boan Biotechnology Co's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.82.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shandong Boan Biotechnology Co's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.35.
Shandong Boan Biotechnology Co (FRA:UJ9) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Shandong Boan Biotechnology Co's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shandong Boan Biotechnology Co's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Shandong Boan Biotechnology Co Days Inventory Related Terms
Shandong Boan Biotechnology Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co Days Inventory Chart
FRA:UJ9 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co (FRA:UJ9) has a Days Inventory of 222.57 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shandong Boan Biotechnology Co and its competitors. This is 22% below median its historical median of 284.24. Over the past decade, Shandong Boan Biotechnology Co's Days Inventory has ranged from 238.58 to 412.22. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #384 out of 638 companies in the Biotechnology industry, placing it in the top 60.2%.
Is Shandong Boan Biotechnology Co's Days Inventory too high?
Shandong Boan Biotechnology Co's current Days Inventory of 222.57 is 22% below median its 10-year median of 284.24. Over the past 10 years, this metric has ranged from a low of 238.58 to a high of 412.22. The Biotechnology industry median Days Inventory is 183.20. Shandong Boan Biotechnology Co's value of 222.57 is 21.5% above this industry median. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #384 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #384 out of 638 companies for Days Inventory. This places Shandong Boan Biotechnology Co in the lower half of its industry. The industry median Days Inventory is 183.20. Shandong Boan Biotechnology Co's value of 222.57 is 21.5% above this benchmark. Historically, Shandong Boan Biotechnology Co's own Days Inventory has ranged from 238.58 to 412.22 over the past decade. While the company's 10-year median is 284.24 vs. the industry median of 183.20, Shandong Boan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Boan Biotechnology Co's current Days Inventory of 222.57 is 21.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shandong Boan Biotechnology Co and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Boan Biotechnology Co's current Days Inventory is 222.57, which is 22% below median its own 10-year median of 284.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Days Inventory of 222.57. The stock's GF Value™ is €1.72, compared to a current price of €0.61 — trading 64.8% below its estimated fair value. The current Days Inventory is 222.57, which is 22% below median its 10-year median of 284.24 and 21.5% above the Biotechnology industry median of 183.20. Shandong Boan Biotechnology Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Days Inventory is 222.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.61 is trading 64.8% below its estimated GF Value™ of €1.72.
Key valuation signals for FRA:UJ9:
Days Inventory: 222.57 (22% below median its 10-year median of 284.24)
GF Value™: €1.72 vs. price of €0.61 (64.8% below fair value)
Industry Position: 21.5% above the Biotechnology median (#384 of 638)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Business Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
39GF Score
Get the complete analysis for FRA:UJ9
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
